These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 34853264

  • 1. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
    Saito Y, Takekuma Y, Komatsu Y, Sugawara M.
    Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
    Yerram P, Kansagra S, Abdelghany O.
    J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [Abstract] [Full Text] [Related]

  • 9. Investigation of Prescription Status and Exploration of Risk Factors Related to Denosumab-Induced Hypocalcemia in Combination Therapy with 1α,25-Dihydroxy-vitamin D3.
    Ikegami K, Saito M, Imai S, Kizaki H, Yasumuro O, Funakoshi R, Hori S.
    Biol Pharm Bull; 2023 Sep; 46(1):95-101. PubMed ID: 36596529
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use and safety of denosumab in cancer patients.
    Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Baró N.
    Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
    [Abstract] [Full Text] [Related]

  • 12. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S.
    Endocr J; 2016 May 31; 63(5):479-84. PubMed ID: 26860123
    [Abstract] [Full Text] [Related]

  • 13. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
    Nasser SM, Sahal A, Hamad A, Elazzazy S.
    J Oncol Pharm Pract; 2019 Dec 31; 25(8):1846-1852. PubMed ID: 31694497
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Osteoporos Int; 2019 Jan 31; 30(1):241-249. PubMed ID: 30187112
    [Abstract] [Full Text] [Related]

  • 18. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W.
    Osteoporos Int; 2018 Aug 31; 29(8):1737-1745. PubMed ID: 29713798
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V, Chiang CY, Booth J, Mount PF.
    Am J Nephrol; 2015 Aug 31; 41(2):129-37. PubMed ID: 25790847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.